Vaccines

Five things for pharma marketers to know: Monday, February 22, 2016

Five things for pharma marketers to know: Monday, February 22, 2016

Merck CEO says industry needs to better communicate value; procedural vote could clear Califf as FDA chief; HPV vaccine lowers virus' prevalence

Five things for pharma marketers to know: Friday, February 19, 2016

Five things for pharma marketers to know: Friday, February 19, 2016

By

Cancer MoonShot 2020 to study childhood cancers; IBM's purchase of Truven provides data about 200 million patients; overdoses tied to benzodiazepines rise

Paul Newman to lead Takeda's vaccines comms

Paul Newman to lead Takeda's vaccines comms

By

The former MSL regional leader reemerges as head of communications at Japan's largest pharma company.

Pfizer delivers strong Prevnar sales on back of big '15 consumer media outlay

Pfizer delivers strong Prevnar sales on back of big '15 consumer media outlay

By

Company's vaccines chief credits campaigns aimed at grownups with driving US demand for blockbuster vaccine. The remaining cohort will be harder to capture.

Five things for pharma marketers to know: Tuesday, September 15, 2015

Five things for pharma marketers to know: Tuesday, September 15, 2015

By

GSK awards its global media buying business; one-third of patients dropped out of Xenoport psoriasis trial; an experimental drug for liver disease fails to meet primary endpoints

Is It Time to Change the Vaccine Dialogue? Campaigns Present Opportunities for Pharma

Is It Time to Change the Vaccine Dialogue? Campaigns Present Opportunities for Pharma

While social media can be a tool for pharma to help educate the public, it has also become a forum for the public to express their views about pharma, and it's not always flattering, as evidenced by the recent antivaccine movement.

Five things for pharma marketers to know: Thursday, July 2

Five things for pharma marketers to know: Thursday, July 2

By

Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs

Pfizer reports uptake for cancer-therapy Ibrance

Pfizer reports uptake for cancer-therapy Ibrance

By

Sales of the new cancer drug topped expectations since its February launch.

Five things for pharma marketers to know: Wednesday, April 22

Five things for pharma marketers to know: Wednesday, April 22

By

Study finds vaccines still not linked to autism; investments in healthcare start-ups hit record high this year; biosimilars are already bearing down on prices overseas

Five things for pharma marketers to know: Thursday, April 2

Five things for pharma marketers to know: Thursday, April 2

By

Celltrion expects its Remicade biosimilar to hit the US this year; Vivus cuts its sales force; BMJ accuses Novartis of interfering with clinical trials

Five things for pharma marketers to know: Tuesday, February 24

Five things for pharma marketers to know: Tuesday, February 24

By

FDA approves Novartis's Farydak for multiple myeloma; Shire acquires rare-disease drug for $70 million; FTC fines melanoma app marketers.

Five things for pharma marketers to know: Monday, February 9

Five things for pharma marketers to know: Monday, February 9

By

Achillion's experimental HCV drug cleared the virus in six weeks when combined with Gilead's Sovaldi; Sanofi will replace a third of its sales managers; GSK shutters Montana vaccine R&D.

Education effort provides measles/pertussis cheat sheet

Education effort provides measles/pertussis cheat sheet

By

Measles outbreak news aside, doctors need help identifying illnesses vaccines have made uncommon.

Five things for pharma marketers to know: Monday, February 2

Five things for pharma marketers to know: Monday, February 2

By By

Pfizer ends spinal muscular atrophy collaboration; abuse-deterrent Zohydro scores approval; measles outbreak at Disneyland linked to 36 cases.

Approval pits Novartis meningococcal vaccine against Pfizer shot

FDA has approved Novartis's Bexsero after approving Pfizer's Trumemba this past October.

Five things for pharma marketers to know: Tuesday, January 20

Five things for pharma marketers to know: Tuesday, January 20

By

FDA draws fine line between health and wellness apps; Colorado gives biosimilar swap law another look; ZMapp is set to start human trials of its Ebola vaccine.

J&J inks Alzheimer's vaccine deal

The $509-million agreement gives J&J rights to AC Immune's experimental anti-Tau vaccine.

Gates Foundation sponsors campaign to promote vaccinations

The artwork is meant to inspire debate and donations for vaccinations.

Five things for pharma marketers to know: Tuesday, January 6

Five things for pharma marketers to know: Tuesday, January 6

By

Pfizer continues to scoop up vaccine assets, Dendreon heads to auction with no lead bidder, Genentech and 23andMe will take on the Parkinson's genome.

GSK shingles vax shaping up to compete with Merck's

GSK shingles vax shaping up to compete with Merck's

By

The Herpes zoster vaccine candidate showed relatively strong efficacy in a Phase-III trial, but its dosing is less convenient than an older product sold by rival Merck.

Pfizer urges parents to take the pledge against meningitis

Pfizer urges parents to take the pledge against meningitis

By

Pfizer has kicked off a disease-awareness campaign, "Take Action Against Meningitis," urging parents to discuss vaccinations with their healthcare providers with paralympic snowboarder Amy Purdy.

Five things for pharma marketers to know: Monday, December 1

Five things for pharma marketers to know: Monday, December 1

By By

GSK is set to announce US job cuts this week, sales reps are getting the axe in China, and the FDA has rejected Avanir's inhalable migraine medication.

NIH tests second Ebola vax in humans

Canada's National Microbiology Laboratory developed the vaccine, which has been licensed to NewLink Genetics Corp.

Five things for Pharma Marketers to Know: Thursday, August 28

Five things for Pharma Marketers to Know: Thursday, August 28

By

Human testing of GSK's Ebola virus starts next week, menopause is a costly healthcare concern, and a small conversation with pharmacists may have a big impact.

Endorsement could boost Pfizer vax

Endorsement could boost Pfizer vax

By

It could also eat into Merck's Pneumovax sales.

EU mulls new Prevnar 13 indication

A greenlight could garner Pfizer $1B in sales.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.

Study finds delaying vaccines is risky

Study finds delaying vaccines is risky

By

A study shows that veering off the recommended vaccination schedule ups the risk for childhood seizures.

CDC: un-vaccinated behind measles outbreak

The CDC said Thursday that most of the 288 recent US measles cases were caused by un-vaccinated travelers who brought the virus home with them.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

By

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

OPINION


Click here to learn about the Agency Issue. 

Email Newsletters